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AbstrAct
Objective Although vasodilators are used in acute heart 
failure (AHF) management, there have been no clear 
supportive evidence regarding their routine use. Recent 
European guidelines recommend systolic blood pressure 
(SBP) reduction in the range of 25% during the first 
few hours after diagnosis. This study aimed to examine 
clinical and prognostic significance of early treatment with 
intravenous vasodilators in relation to their subsequent 
SBP reduction in hospitalised AHF.
Methods We performed post hoc analysis of 1670 
consecutive patients enrolled in the Registry Focused 
on Very Early Presentation and Treatment in Emergency 
Department of Acute Heart Failure. Intravenous vasodilator 
use within 6 hours of hospital arrival and subsequent SBP 
changes were analysed. Outcomes were gauged by 1-year 
mortality and diuretic response (DR), defined as total urine 
output 6 hours posthospital arrival per 40 mg furosemide-
equivalent diuretic use.
Results Over half of the patients (56.0%) were treated 
with intravenous vasodilators within the first 6 hours. In 
this vasodilator-treated cohort, 554 (59.3%) experienced 
SBP reduction ≤25%, while 381 (40.7%) experienced 
SBP reduction >25%. In patients experiencing ≤25% drop 
in SBP, use of vasodilator was associated with greater 
DR compared with no vasodilators (p<0.001). Moreover, 
vasodilator treatment with ≤25% drop in SBP was 
independently associated with lower all-cause mortality 
compared with those treated without vasodilators 
(adjusted HR 0.74, 95% CI 0.57 to 0.96, p=0.028).
Conclusions Intravenous vasodilator therapy was 
associated with greater DR and lower mortality, provided 
SBP reduction was less than 25%. Our results highlight 
the importance in early administration of intravenous 
vasodilators without causing excess SBP reduction in AHF 
management.
Clinical trial registration URL: http://www. umin. ac. jp/ 
ctr/ Unique identifier: UMIN000014105.
IntROduCtIOn
Vasodilators optimise preload and after-
load by decreasing venous and arterial tone 
and consequently lower systolic blood pres-
sure (SBP) and increase stroke volume.1–3 
Although it is common clinical practice to 
use vasodilators in the management of acute 
heart failure (AHF) in accordance with 
the current guidelines,2 4 there has been 
no clear supportive evidence regarding the 
routine use of intravenous vasodilators and 
clinical trials currently performed resulted in 
neutral results in terms of prognostic effect.5 6 
This is in part due to the variability of patients’ 
baseline volume and perfusion status and 
their propensity to maintain adequate circu-
lation by intravascular refill following aggres-
sive diuresis. In addition, most of the previous 
AHF studies have enrolled patients relatively 
late timing,7–12 and role of vasodilators in very 
acute phase in patients with AHF remains 
unclear. While most studies have a lower SBP 
threshold to withhold vasodilator therapy, 
there are unavoidable concerns regarding 
the negative prognostic impact of excessive 
SBP fall accompanying vasodilator use—in 
many cases reactive and likely too late in 
Key questions
What is already known about this subject?
 ► Intravenous vasodilators are recommended in acute 
heart failure (AHF) management, but there have 
been no clear supportive evidence regarding their 
routine use. Excessive blood pressure reduction is 
associated with worse outcomes in patients with 
AHF.
What does this study add?
 ► Early therapy using intravenous vasodilators with 
subsequent blood pressure reduction less than 25% 
from baseline was associated with better diuretic 
response and prognosis in hospitalised AHF com-
pared with those treated without vasodilators.
How might this impact on clinical practice?
 ► Our results highlight the importance in early admin-
istration of intravenous vasodilators without caus-
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preventing adverse consequences. Indeed, some studies 
have shown that SBP fall in the acute setting of AHF was 
associated with worse renal and clinical outcomes.13–15 As 
a result, the latest European guidelines recommend their 
use in targeting a range of SBP reductions within 25% 
from baseline during the first few hours.2 Nevertheless, 
this cut-off value is not based on enough evidence, and 
the clinical and prognostic impact of SBP reduction by 
acute-phase intravenous vasodilators has not been care-
fully investigated. Herein, we examine the clinical and 
prognostic impact of very early treatment with intrave-
nous vasodilators in relation to SBP reduction in hospi-
talised patients with AHF.
MetHOds
study population
The Registry Focused on Very Early Presentation and 
Treatment in Emergency Department of Acute Heart 
Failure (REALITY-AHF) study was designed to deter-
mine the prognostic impact of time-to-treatment for AHF 
performed in the very acute phase in the emergency 
department. The study design and primary results have 
been reported elsewhere in detail, with unique capture of 
data at the earliest clinical encounter prior to administra-
tion of intravenous diuretics that provides the feasibility 
for our post hoc analysis.16 Briefly, the REALITY-AHF study 
was a multicenter prospective registry, which included 
1682 consecutive hospitalised patients diagnosed with 
AHF in the emergency department within 3 hours of the 
first evaluation by caregivers. Exclusion criteria were: (1) 
treatment with an intravenous drug performed prior to 
ED arrival, (2) previous heart transplantation, (3) on 
either chronic peritoneal dialysis or haemodialysis, (4) 
acute myocarditis and (5) acute coronary syndrome 
requiring emergent/urgent revascularisation. Patients 
with missing brain natriuretic peptide (BNP) or N-termi-
nal-proBNP data and those with a BNP level <100 pg/mL 
or N-terminal-proBNP level <300 pg/mL at baseline were 
also excluded.
Vasodilator use and sBP reduction in acute phase
Each patient enrolled in the REALITY-AHF study under-
went a detailed baseline assessment including physical 
examination, vital signs, haemodynamic assessment if 
needed, echocardiography, medical history and medi-
cations. The ‘time zero’ was set at the exact time of 
emergency department arrival, and SBP was measured 
and recorded at baseline, 90 min, 6 hours, 24 hours and 
48 hours after patients’ emergency department arrival.
As our main purpose of this study is to investigate the 
association between vasodilator use and SBP reduction 
in the very acute phase of AHF management, we focused 
on 6-hour period from patients’ emergency department 
arrival. SBP reduction was defined as per cent reduction 
in SBP from baseline to at 90 min or 6 hours, whichever 
was lower. According to the latest European guidelines 
recommendation,2 patients were categorised into three 
groups: no vasodilator treatment, vasodilator treatment 
yielding a BP reduction of ≤25% and vasodilator treat-
ment yielding a BP reduction of >25% within 6 hours of 
emergency department arrival.2
Outcomes
We evaluated diuretic response (DR) and 1 year all-cause 
mortality as outcomes. The DR was defined as a total urine 
output achieved at 6 hours from the patient’s hospital 
arrival per 40 mg furosemide-equivalent diuretics use.16 
Oral furosemide was converted to half dose of intrave-
nous furosemide. The doses of other oral loop diuretics 
that were considered equivalent to 40 mg intravenous 
furosemide were 10 mg torsemide and 60 mg azosemide.
The 1 year all-cause mortality was defined from the day 
of admission. Patient status was prospectively tracked for 
all patients with medical chart review and confirmed by 
follow-up contact. For those followed-up in other institu-
tion from where the patient was registered, prognostic 
data were obtained from telephone interviews by the 
medical records department of other medical facilities 
caring for the patient or from information given by family 
members.
statistical analysis
Categorical variables are shown as numbers and percent-
ages. Continuous variables are expressed as mean and 
SD or median and IQR where appropriate. The relation-
ship between groups and baseline characteristics were 
tested using the one-way analysis of variance, Kruskal-
Wallis or Χ2 tests, where appropriate. When neces-
sary, variables were transformed for further analysis. A 
multivariable Cox proportional hazards model with the 
following risk-adjusting variables was constructed to esti-
mate the adjusted HR, including age, gender, baseline 
SBP, heart rate at admission, left ventricular ejection 
fraction (LVEF), history of diabetes mellitus, history of 
heart failure, serum creatinine, haemoglobin, sodium 
levels, blood urea nitrogen, BNP levels, prescription of 
beta-blocker and ACE inhibitor (ACEI) or angiotensin 
receptor antagonist (ARB) at admission. Graphical 
inspection of Schoenfield residuals plotted against time 
was performed to ensure proportional hazards assump-
tion was not violated. All variables were selected a priori 
as they were either predictors of risk in heart failure 
or because of their ability to confound the results. We 
performed exploratory analysis to evaluate the asso-
ciation between SBP fall within 6 hours of emergency 
department arrival and 1 year all-cause death. We used a 
restricted cubic spline to visualise adjusted HR calculated 
by multivariable Cox regression model. Same variables as 
used in the Cox regression model were used for adjust-
ment in restricted cubic spline model. Knots were placed 
at the 10th, 50th, and 90th percentiles (−41.6%, −16.7% 
and +4.3%, respectively). Further, interaction analyses 
among baseline SBP, SBP fall within 6 hours and 1-year 
mortality were performed. All statistical analyses were 
performed with the statistical software R (V.3.1.2, Vienna, 
 o
n
 11 February 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000845 on 11 July 2018. Downloaded from
 
3Kitai T, et al. Open Heart 2018;5:e000845. doi:10.1136/openhrt-2018-000845
Heart failure and cardiomyopathies




Overall, median SBP reduction rate from baseline to 
6 hours from hospital arrival was 17.4 (IQR 5.1–20)%. 
During the first 6 hours after patient arrival in hospital, 
intravenous vasodilator therapy was performed in 935 
patients (56.0%). In this vasodilator-treated cohort, 554 
(59.3%) exhibited a SBP reduction of ≤25% from base-
line, while 381 (40.7%) experienced a SBP reduction 
of >25% (figure 1). Comparisons of baseline characteris-
tics among these groups are provided in table 1. Patients 
treated with vasodilator yielding a SBP reduction >25% 
had significantly higher blood pressure (BP) and heart 
rate at baseline and higher prevalence of hypertension. 
Although age and BNP levels were similar among the 
three groups, serum creatinine levels were significantly 
higher in patients treated with vasodilators yielding a SBP 
reduction of ≤25%.
Blood pressure changes and diuretic response
In the overall registry, the mean SBP was 149±37 mm Hg 
at baseline and 123±23 mm Hg at 6 hours from hospital 
arrival. Although patients treated with vasodilator yielding 
a SBP reduction of >25% had the highest baseline SBP 
among the three groups (p<0.001), SBP at 6 hours 
from baseline was the highest in patients treated with 
vasodilator yielding a SBP reduction of ≤25% (p<0.001, 
figure 2).
Patients treated with vasodilators yielding a SBP reduc-
tion of ≤25% showed significantly better DR than the 
other two groups (p<0.001, figure 3). Furthermore, 
vasodilator therapy yielding a SBP reduction of ≤25% 
(p<0.001) was associated with greater DR compared with 
those treated without vasodilators even after adjusting 
for confounders (table 2). However, no significant differ-
ence in DR was observed for patients with >25% drop in 
SBP compared with those without vasodilator treatment 
(p=0.915).
Blood pressure changes and mortality
Patient status at 1 year was obtained in 92.8% of all the 
patients. During a follow-up period of 1 year, 346 (19.7%) 
deaths were observed. The figure 4 depicts the contin-
uous relationship between SBP changes from baseline to 
6 hours and 1-year mortality. We observed that greater SBP 
reduction from baseline was associated with higher 1-year 
mortality. Furthermore, patients treated with vasodilators 
yielding SBP reduction ≤25% were associated with lower 
all-cause mortality compared with those treated without 
vasodilators, even after adjusting for confounders 
(adjusted HR 0.74, 95% CI 0.57 to 0.96, p=0.028, table 3). 
In contrast, those experienced >25% reduction in BP was 
not associated with lower all-cause mortality.
As an exploratory analysis, we evaluated the associa-
tion between adjusted HR for 1-year mortality and SBP 
Figure 1 Study patient flow. REALITY-AHF, Registry Focused on Very Early Presentation and Treatment in Emergency 
Department of Acute Heart Failure; SBP, systolic blood pressure.
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reduction during the first 6 hours from baseline. There 
was no statistically significant interaction between base-
line SBP and SBP reduction (as a continuous scale) (p 
for interaction=0.909) and with/without vasodilator 
treatment and SBP reduction (p for interaction=0.692) 
on 1-year mortality.









P valuesn=735 n=554 n=381
Age, years 78±12 77±13 77±12 0.191
Male 390 (53.1) 329 (59.4) 207 (54.3) 0.068
Cardiovascular disease 411 (56.7) 307 (56.0) 220 (59.1) 0.626
Pulmonary rate 440 (60.1) 344 (62.2) 314 (82.4) <0.001
Peripheral oedema 503 (68.6) 410 (74.0) 230 (60.5) <0.001
Baseline systolic BP, mm Hg 135±31 141±27 188±32 <0.001
Baseline diastolic BP, mm Hg 76±20 79±21 104±28 <0.001
Baseline heart rate, bpm 94±28 94±28 109±27 <0.001
Heart rhythm
  Sinus rhythm 362 (49.6) 300 (54.2) 244 (64.2) <0.001
  Atrial fibrillation 286 (39.2) 191 (34.5) 112 (29.5)
  Others 82 (11.2) 62 (11.2) 24 (6.3)
Left ventricular ejection fraction, %
  35 262 (38.8) 201 (37.6) 128 (36.1) 0.519
  35–50 189 (28.0) 149 (27.9) 116 (32.7)
  50 225 (33.3) 184 (34.5) 111 (31.3)
Prior history of heart failure 408 (55.6) 285 (51.4) 155 (40.7) <0.001
Comorbidities
  Hypertension 445 (60.5) 378 (68.5) 297 (78.0) <0.001
  Diabetes mellitus 242 (32.9) 219 (39.7) 155 (40.7) 0.01
  Chronic obstructive pulmonary disease 78 (10.6) 36 (6.6) 37 (9.8) 0.038
  Coronary artery disease 188 (25.6) 188 (34.1) 126 (33.1) 0.002
Medications
  Loop diuretics 413 (56.3) 292 (53.1) 139 (37.0) <0.001
  ACE inhibitors or angiotensin receptor 
antagonist
0.44 (0.50) 0.46 (0.50) 0.50 (0.50) 0.171
  Beta blocker 314 (43.0) 243 (43.9) 155 (41.2) 0.713
  MR angiography 207 (28.2) 105 (19.0) 59 (15.5) <0.001
Laboratory data
  White cell count 7050 (5600, 9400) 7300 (5600, 9575) 8900 (6900, 11 800) <0.001
  Haemoglobin 11.6±2.2 11.6±2.34 12.1±2.41 <0.001
  Aspartate aminotransferase 31 (23, 47) 30 (22, 46) 32 (24, 48) 0.687
  Alanine aminotransferase 22 (13, 37) 22 (14, 37) 21 (14, 36) 0.501
  Creatinine 1.08 (0.81, 1.56) 1.22 (0.87, 1.78) 1.09 (0.84, 1.44) 0.001
  Blood urea nitrogen 25 (18, 36) 26 (19, 39) 23 (17, 31) <0.001
  Sodium 138±5 139±5 140±4 <0.001
  Glucose 155±73 160±75 199±86 <0.001
  C-reactive protein 0.75 (0.22, 2.24) 0.85 (0.26, 2.55) 0.45 (0.13, 1.21) <0.001
  Brain natriuretic peptide 710 (452, 1312) 794 (432, 1556) 745 (457, 1150) 0.086
BP, blood pressure. 
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dIsCussIOn
The current post hoc analysis of the REALITY-AHF study 
investigated the association between intravenous vaso-
dilator therapy in the very acute phase in relation to 
accompanying SBP fall, the DR and 1-year mortality in 
1670 hospitalised patients with AHF. The major finding 
of this study was that early intravenous vasodilator therapy 
was associated with greater DR and reduced 1-year 
Figure 2 Comparison of changes in systolic blood pressure among patients not receiving intravenous vasodilator therapy and 
those receiving vasodilators yielding blood pressure (BP) reductions >25% and ≤25%.
Figure 3 Comparisons of diuretic response at 6 hours from hospital arrival.
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mortality provided that the reduction of SBP from base-
line was not higher than 25%, which supports the latest 
European guideline recommendations.2 Our results 
highlight the need to focus on careful patient selection 
and treatment monitoring with vasodilator use to achieve 
the most optimal outcomes.
The role of vasodilators in the management of AHF is 
pivotal.17 18 Traditional vasodilators such as nitrates are 
the second most commonly (after diuretics) administered 
drug category in the management of AHF.19–24 Intrave-
nous vasodilators lead to afterload reduction, vascular 
redistribution and consequently to the relief of symp-
toms such as dyspnoea.17 A recent meta-analysis demon-
strated similar improvement of left-sided and right-sided 
filling pressures by vasodilators or inotropes in patients 
with AHF with reduced LVEF.25 According to the guide-
lines, BP reduction and the use of intravenous vasodila-
tors combined with diuretics for the relief of dyspnoea 
is recommended in patients admitted with AHF, in the 
absence of hypotension.2 4 However, few studies have 
focused on understanding the clinical impact of SBP 
reduction via the short-term use of intravenous vasodila-
tors early in the course of AHF management.13 Although 
the routine use of intravenous vasodilators in the acute 
phase can lower BP and improve short-term symptoms 
in patients with AHF, it does not influence long-term 
outcomes.7–12 26 The present analysis highlights the fact 
that early administration of intravenous vasodilators in 
patients with AHF may be accompanied by favourable 
1-year survival, provided that the SBP fall during treat-
ment does not exceed the 25% compared with its base-
line values.
Arterial dilating effects of vasodilators can be useful 
in patients with heart failure with higher peripheral 
arterial tone (ie, hypertensive patients), and venous 
dilating actions may exhibit favourable results in patients 
with heart failure with increased ventricular preload.27 
However, the contributory role of vasodilators to the 
management of AHF may be offset by an unfavourable 
effect of SBP reduction.25 A recent study demonstrated 
that a greater early fall in SBP within the first 48 hours after 
hospitalisation for AHF was an independent predictor of 
worsening renal function which correlated with higher 
60-day and 180-day mortality.15 Furthermore, poor DR 
in AHF has been shown to be independently associated 
with low baseline SBP, renal impairment and adverse 
outcomes.28–30 Thus, although vasodilators manifest 
beneficial haemodynamic effects when administered in 
patients with AHF with increased arterial tone, an exces-
sive reduction of SBP may cause low organ perfusion, 
such as renal hypoperfusion, and consequently adverse 
outcomes, whereas a reasonable SBP reduction (ie, in 
the range of 25%) may lead to reduced afterload and 
accordingly to increased cardiac output. Interestingly, 
in the present analysis, patients treated with vasodilator 
yielding a SBP reduction of ≤25% exhibited a greater 
DR compared with those without vasodilator treatment. 
The balance between these favourable and unfavourable 
effects of vasodilators in the acute setting seems to be 
of high clinical importance, as a significant fall in SBP 
and/or hypotensive episodes may cancel their beneficial 
effects: therefore, the use of vasodilators may be accom-
panied by neutral or even adverse outcomes. The fact that 
40.7% in the registry experience rather profound reduc-
tion in SBP (>25% from baseline) following vasodilator 
therapy suggests that such intricate balance of preload 
and afterload to relieve congestion as well as maintain 
circulatory perfusion can be difficult in a large subset 
of patients with AHF especially with concomitant use of 
vasodilator therapy.
Another possible explanation for the favourable prog-
nostic impact of vasodilator treatment in our study is that 
Table 2 Univariate and multivariable linear regression for diuretic response at 6 hours from baseline
Groups
Univariate linear regression for diuretic 
response at 6 hours
Multivariable linear regression for 
diuretic response at 6 hours
B coefficient (95% CI) t value P values B coefficient (95% CI) t value P values
No vasodilators 1 (Reference) 1 (Reference)
Vasodilator and≤25% SBP reduction 459.4 (254.8 to 664.1) 4.40 <0.001 499.2 (268.9 to 729.5) 4.26 <0.001
Vasodilator and>25% SBP reduction 211.6 (−10.8 to 434.0) 1.87 0.062 −12.9 (−249.6 to 223.9) −0.107 0.915
SBP, systolic blood pressure.
Figure 4 The continuous association of systolic blood 
pressure reduction rate and all-cause mortality.
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we investigated the early use of intravenous vasodilator 
(<6 hours of emergency department arrival). Previous 
studies suggested that the efficacy of treatment for AHF 
may be time-dependent.16 31–34 The latest guidelines 
recommend early management and emphasise the time-
to-treatment concept in the management of AHF.2 We 
have recently reported favourable prognostic impacts of 
early diuretic treatment in patients with AHF,16 and time-
to-treatment concept for AHF may be also applicable to 
intravenous vasodilator use. One simple way to explain 
this observation is the fact that earlier administration 
of vasodilator does not have to confront the excessive 
intravascular volume depletion common with aggressive 
intravenous diuretic therapy. Hence, optimal balancing 
of congestion relief can be achieved without compro-
mising organ perfusion, which is far more likely when 
plasma refill rate is low. The RELAITY-AHF study which 
focused on the very acute phase treatment for AHF is a 
unique dataset which enabled us to evaluate time-depen-
dent treatment efficacies in the management of AHF. 
Our results highlight the importance of intravenous vaso-
dilator administration, provided the SBP reduction is 
within the range of 25% in the early treatment for AHF.
limitations
There are several limitations inherent in the post hoc 
retrospective analysis design. First, we do not have infor-
mation regarding vasodilator dosage, nor did we analyse 
the specific type of vasodilators. Second, this was not a 
predefined analysis, but a post hoc analysis from a registry, 
and thus treatment with vasodilators was not randomised. 
Third, although all the three groups had follow-up rate 
higher than 90%, relatively low rate in the group of vaso-
dilator use and ≤25% SBP reduction may influence the 
results. Finally, despite covariate adjustment, we cannot 
exclude the influence of other measured and unmeas-
ured confounders. Nonetheless, REALITY-AHF was a 
well-designed and large-scale data set, which enabled us 
to assess the trajectory of BP in the very acute phase of 
AHF, and to gain a new perspective on the role of vasodi-
lators in AHF management.
COnClusIOns
Intravenous vasodilator therapy was associated with 
greater DR and lower mortality, provided the SBP reduc-
tion subsequently achieved was less than 25%. Our results 
highlight the clinical and prognostic importance of the 
timely use of intravenous vasodilators which do not cause 
excessive SBP lowering in the treatment of AHF.
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